Drugs by Therapeutic Area Market Research

Total Records (555)
Show

Omega 3 Market By Type (ALA (Alpha-Linolenic Acid), DHA (Docosahexaenoic Acid), EPA (Eicosapentaenoic Acid) ), By Source (Marine, Nuts And Seeds, Vegetable Oils, Soya And Soya Products), By Application (Dietary Supplements, Pharmaceutical, Infant Formula, Food & Beverages, Pet Food, Fish Feed) - Growth, Future Prospects And Competitive Analysis, 2026 - 2034

Omega 3 fatty acids are a type of fat that are considered essential for overall health of humans. A lot of health experts recommend the same and a lot of research has went into discovering the many health benefits of omega-3 fatty acids.

4500.00
29 Oct, 2017

Hyperbaric Oxygen Therapy (HBOT) Devices Market By Device Type (Monoplace & Multiplace HBOT Devices) By Application (Wound Healing, Decompression Sickness, Air Or Gas Embolism, Infection Treatment & Others) - Growth, Future Prospects & Competitive Analysis, 2021 – 2029

The global hyperbaric oxygen therapy (HBOT) devices market is anticipated to reach US$ 368.36 Mn by 2029. Increasing preference of physicians to use oxygen therapy has been greatly contributing to the market growth of HBOT devices. HBOT devices have received FDA approval for treatment of necrotizing soft tissue infection, injuries, burns, decompression sickness and others. Off-label use of HBOT devices encompasses treatment of brain injuries and even cancer, despite lack of robust clinical evidence.

4325.00
10 Mar, 2019

Aspergillosis Treatment Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025

According to the Cleveland Clinic, Aspergillosis is an infection or allergic reaction caused by various kinds of molds found on plants, soil, building materials or rotting vegetables. Aspergillosis treatment market can be segmented on the basis of several types such as allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis and cutaneous (skin) aspergillosis. ABPA is observed as one of the most common aspergillosis in which inflammation in the lungs and allergy symptoms such as coughing and wheezing are observed.

4325.00
27 Sep, 2016

Krill Oil Market by Product Type (Liquid, Tablet), by Application (Fortified Food & Beverages, Animal Feed, Dietary Supplements, Pharmaceuticals, Others), by Distribution Channel (Supermarkets/Hypermarkets, Departmental Store, Pharmacy Store, Online Store, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Krill are small, up to 6 cm, shrimplike shellfish at the base of the ocean’s food chain. Including 85 species of krill, the total estimated biomass of between 400 Mn and 600 Mn tones in 2016-17. For claimed health benefits of krill oil, including the management and treatment of conditions, such as hyperlipidemia, inflammation, and arthritis, there has been a noticeable increase in research and promotion of krill oil in recent years.

4325.00
29 Aug, 2018

Amyloidosis Therapeutic Treatment Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025

Amyloidosis is a rare disease causes due to building up of amyloid an abnormal protein which usually gets produced in bone marrow and deposits in any tissue or organ. According to The Amyloidosis Foundtion, in the U.S. amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from age group 50-80; however, there are a few cases of people being diagnosed as early as their late 20s and overall incidence statistics suggest that two-thirds of the patients are male.

4325.00
26 Sep, 2016

Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, By End Use - Growth, Share, Opportunities & Competitive Analysis, 2025 – 2033

Nonalcoholic steatohepatitis (NASH) reatment market is Expected to Grow at 38% by 2033. Nonalcoholic steatohepatitis (NASH) is also known as ‘fatty liver’ a disorder that develops in patients who are not alcoholic; mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to poor understanding of pathogenesis linked to insulin resistance especially in obesity or metabolic syndrome.

4500.00
05 May, 2023

Primary Biliary Cholangitis (PBC) Treatment Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025

According to American Liver Foundation, primary biliary cholangitis formerly known as primary biliary cirrhosis (PBC), is a chronic liver disease that gradually destroys the medium-sized bile ducts within the liver. These bile ducts are damaged by inflammation which causes bile to remain in the liver, where gradual injury damages liver cells and causes liver cirrhosis. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver loses its ability to function

4325.00
29 Aug, 2016

Grape Seed Extracts Market By Form Type (Powder, Liquid, and Gel), By Application (Food, Pharmaceutical, Personal care and others) - Growth, Share, Opportunities & Competitive Analysis, 2021 - 2029

Grape seed extracts is an industrial derivative of grape seeds; it contains a vast array of health-benefiting ingredients, such as carbohydrates, protein, polyphenols and lipids. Grape seed extracts also protect the blood vessel walls from inflammatory stress, the brain from low oxygen states and the skin from UV radiation damage. Due to its benefits on these systems, it has been shown to reduce the risk of skin cancer, protect against dementia and improve blood pressure.

4325.00
21 Aug, 2016

Thyroid Gland Disorders Treatment Market By Treatments (Hypothyroidism, Hyperthyroidism) - Growth, Share, Opportunities & Competitive Analysis, 2026 - 2034

The thyroid gland disorders treatment market is propelling due to the factors such as rise in the patient base suffering from thyroid disorders, rising geriatric population and consistent introduction of innovative and novel therapeutics by market players leading to the growth of the market. Asia Pacific is expected to be the fastest growing market in the thyroid gland disorder treatment market due large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in the countries such as China, India and Japan.

4325.00
10 Aug, 2016

Ophthalmic Drugs Market By Prescription Type (Prescription Ophthalmic Drugs, OTC), By Therapeutics (Glaucoma, Retinal Disorder, Dry Eye, Allergic Conjunctivitis) - Growth, Share, Opportunities & Competitive Analysis, 2021 - 2029

Geriatric population is growing with the rising global population, and rising patient base suffering from ocular and eye related disorders has been a major growth driver that have urged the advent of ophthalmic drugs market. In the next few years the demand for ophthalmic drugs is expected to increase significantly in the emerging economies such as China and India.

4325.00
04 Oct, 2021
Filter

Key Sectors

The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.

The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.

Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.

Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.

Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.

Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.

Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.

Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.